Real Heart (ST:HEART) — Market Cap & Net Worth
Market Cap & Net Worth: Real Heart (HEART)
Real Heart (ST:HEART) has a market capitalization of $9.17 Million (Skr85.23 Million) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #27385 globally and #597 in its home market, demonstrating a -6.58% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Real Heart's stock price Skr17.05 by its total outstanding shares 4998704 (5.00 Million). Also see Real Heart total assets for a full breakdown of the balance sheet.
Real Heart Market Cap History: 2015 to 2026
Real Heart's market capitalization history from 2015 to 2026. Data shows change from $260.38 Million to $9.17 Million (-24.63% CAGR). Also see cash efficiency ratio of Real Heart for how efficiently the company converts equity into cash flow.
Index Memberships
Real Heart is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.31 Billion | 0.06% | #165 of 281 |
Weight: Real Heart's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Real Heart Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Real Heart's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Real Heart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
6738.73x
Real Heart's market cap is 6738.73 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $260.38 Million | $148.05K | -$1.53 Million | 1758.65x | N/A |
| 2016 | $218.79 Million | $132.67K | -$3.88 Million | 1649.12x | N/A |
| 2017 | $189.16 Million | $774.97K | -$13.74 Million | 244.08x | N/A |
| 2018 | $367.27 Million | $111.35K | -$8.86 Million | 3298.43x | N/A |
| 2022 | $67.39 Million | $10.00K | -$13.99 Million | 6738.73x | N/A |
Competitor Companies of HEART by Market Capitalization
Companies near Real Heart in the global market cap rankings as of September 19, 2026. Review HEART tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Real Heart by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #126 globally with a market cap of $177.76 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #229 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #235 globally with a market cap of $107.45 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #241 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Abbott Laboratories | NYSE:ABT | $177.76 Billion | $102.23 |
| #229 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.77 |
| #235 | Stryker Corporation | NYSE:SYK | $107.45 Billion | $280.13 |
| #241 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Real Heart Historical Marketcap From 2015 to 2026
Between 2015 and today, Real Heart's market cap moved from $260.38 Million to $ 9.17 Million, with a yearly change of -24.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr9.17 Million | +22.66% |
| 2025 | Skr7.48 Million | +17.20% |
| 2024 | Skr6.38 Million | -68.39% |
| 2023 | Skr20.18 Million | -70.05% |
| 2022 | Skr67.39 Million | -47.17% |
| 2021 | Skr127.55 Million | -10.86% |
| 2020 | Skr143.10 Million | -38.60% |
| 2019 | Skr233.06 Million | -36.54% |
| 2018 | Skr367.27 Million | +94.16% |
| 2017 | Skr189.16 Million | -13.55% |
| 2016 | Skr218.79 Million | -15.97% |
| 2015 | Skr260.38 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Real Heart was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.17 Million USD |
| MoneyControl | $9.17 Million USD |
| MarketWatch | $9.17 Million USD |
| marketcap.company | $9.17 Million USD |
| Reuters | $9.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Real Heart
Scandinavian Real Heart AB (Publ) engages in the design and development of an artificial heart. The company develops Realheart TAH to treat advanced stage heart failure. It also develops RealVAD for pulsating left ventricle assist; PulsePump, a pulsating flow for heart and lung machines; and Sternal Prosthesis to fix the sternum after open-chest surgery. The company was founded in 1999 and is bas… Read more